Breaking News

Globalfoundries to Buy IBM's Chip Unit; IBM Sees Pretax Charge $4.7 Billion
Tweet TWEET

Tranzyme Pharma Announces Resignation of Chief Financial Officer

Tranzyme Pharma Announces Resignation of Chief Financial Officer

RESEARCH TRIANGLE PARK, N.C., Dec. 5, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma
(Nasdaq:TZYM), today announced that Richard I. Eisenstadt, Vice President,
Finance and Chief Financial Officer, has resigned effective January 4, 2013,
to pursue a new career opportunity.

"On behalf of the entire team at Tranzyme Pharma, I would like to thank Rich
for his many years of hard work and dedication at the Company during his
tenure as CFO. Since joining Tranzyme in 2003, Rich has been a valuable member
of our executive team. We wish him the best in his future endeavor," said
Vipin K. Garg, Ph. D., President and CEO of Tranzyme Pharma.

Upon the effective date of Mr. Eisenstadt's resignation, Tranzyme's
Controller, Rhonda L. Stanley will perform the duties of principal financial
officer and principal accounting officer of the Company.

About Tranzyme Pharma

Tranzyme Pharma is a clinical-stage biopharmaceutical company focused on
discovering, developing and commercializing novel, mechanism-based
therapeutics for the treatment of upper gastrointestinal (GI) motility
disorders. While approximately 40 percent of people in the U.S. are affected
by these persistent and recurring conditions which disrupt the normal movement
of food throughout the GI tract, there are a limited number of safe and
effective treatment options. Tranzyme is developing TZP-102, an oral ghrelin
agonist for treating the symptoms associated with chronic upper GI motility
disorders. Tranzyme is currently enrolling patients in a Phase 2b trial
(DIGEST) evaluating TZP-102 given prior to meals in diabetic patients with
gastroparesis; top-line data are expected in the first half of 2013. By
leveraging its proprietary drug discovery technology, MATCH™, Tranzyme is
committed to pursuing first-in-class medicines to address areas of significant
unmet medical needs.

Further information about Tranzyme Pharma can be found on the Company's web
site at www.tranzyme.com.

Forward-Looking Statements

Statements in this press release may include statements which are not
historical facts and are considered forward-looking within the meaning of
Section 27A of the Securities Act and Section 21E of the Securities Exchange
Act, which are usually identified by the use of words such as "anticipates,"
"believes," "estimates," "expects," "intends," "may," "plans," "projects,"
"seeks," "should," "will," and variations of such words or similar
expressions. We intend these forward-looking statements to be covered by the
safe harbor provisions for forward-looking statements contained in Section 27A
of the Securities Act and Section 21E of the Securities Exchange Act and are
making this statement for purposes of complying with those safe harbor
provisions. These forward-looking statements reflect our current views about
our plans, intentions, expectations, strategies and prospects, including the
timing of the availability of data from our clinical trial of TZP-102, which
are based on the information currently available to us and on assumptions we
have made. Although we believe that our plans, intentions, expectations,
strategies and prospects as reflected in or suggested by those forward-looking
statements are reasonable, we can give no assurance that the plans,
intentions, expectations or strategies will be attained or achieved.
Furthermore, actual results may differ materially from those described in the
forward-looking statements and will be affected by a variety of risks and
factors that are beyond our control including, without limitation, risks
related to enrollment and successful completion of our trials, risk of
unforeseen side effects, risks related to our collaborations and risks related
to regulatory approval of new drug candidates. Further information on these
and other factors that could affect the company's financial results is
contained in our public filings with the Securities and Exchange Commission
(SEC) from time to time, including our Form 10-Q for the quarter ended
September 30, 2012 which was filed with the SEC on November 9, 2012, and
subsequent filings with the SEC. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. We assume no obligation to update
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.

CONTACT: Corporate Inquiries:
         Susan Sharpe
         Director, Corporate Communications
         (919) 328-1109
         ssharpe@tranzyme.com
        
         Investor Inquiries:
         David Carey
         Lazar Partners, Ltd.
         (212) 867-1768
         dcarey@lazarpartners.com
 
Press spacebar to pause and continue. Press esc to stop.